Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial (Q28252554)

2

0 references

Debra L Barton

3

0 references

Jeff A Sloan

4

0 references

Pam J Atherton

5

0 references

Denise J Smith

6

0 references

Shaker R Dakhil

7

0 references

Dennis F Moore

8

0 references

James E Krook

9

0 references

Kendrith M Rowland

10

0 references

Miroslaw A Mazurczak

11

0 references

Alan R Berg

12

0 references

George P Kim

Shark cartilage: the Laetrile of the 1990s

13

0 references

language of work or name

English

0 references

publication date

1 July 2005

0 references

published in

Cancer

0 references

volume

104

0 references

issue

1

0 references

page(s)

176-82

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Antineoplastic agents L: isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark Sphyrna lewini

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Shark Cartilage Contains Inhibitors of Tumor Angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Demonstration of immunogenic keratan sulphate in commercial chondroitin 6-sulphate from shark cartilage. Implications for ELISA assays

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Proliferation of shark leukocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Media feeds frenzy over shark cartilage as cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Shark cartilage for cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Skeptics of oral administration of shark cartilage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Measuring the quality of life of cancer patients: a concise QL-index for use by physicians

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Comparison of conditional quality of life terminology and visual analogue scale measurements

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Health state valuations from the general public using the visual analogue scale.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Studies with different types of visual analog scales for measurement of pain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

A critical review of visual analogue scales in the measurement of clinical phenomena

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Procedures for comparing samples with multiple endpoints

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021

Neovastat--a novel antiangiogenic drug for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21107

7 January 2021